I've Just Been Diagnosed with Multiple Sclerosis — What Now?

A diagnosis of MS carries a weight that is hard to describe. It takes most people months to reach diagnosis — often longer in South Africa, where neurologist access outside major cities is limited, and where MS is not always the first thing considered. When the diagnosis finally arrives, it is often a strange combination of confirmation and dread.

Here is what you need to know: MS is serious. It is also increasingly manageable. Modern disease-modifying therapies can dramatically reduce relapse rates, slow disability progression, and in many patients, maintain function for decades. The outcomes for people diagnosed with MS today are substantially better than they were ten or fifteen years ago.

What you do in the months immediately after diagnosis matters. Start here.

What to Do Right Now: Five Steps

Step 1 — Find a neurologist with MS expertise

MS is managed by neurologists. Not all neurologists see large numbers of MS patients — in South Africa, MS is rare enough that you may benefit from a specialist who manages significant MS case volume. Major cities (Johannesburg, Cape Town, Durban) have neurologists with MS focus. If you are in a smaller centre, ask for a referral to a tertiary centre for diagnosis confirmation and DMT initiation.

Your first priority is confirming the diagnosis (was McDonald Criteria used? Were alternative diagnoses excluded?) and establishing your MS type and disease activity level. These determine which DMT is appropriate.

Step 2 — Start a disease-modifying therapy

DMTs do not reverse existing damage — they reduce the rate of new damage. This makes starting early critical: every relapse is a risk of permanent disability accumulation. RRMS diagnosed without DMT is RRMS accumulating damage without protection.

For most newly diagnosed RRMS patients, first-line therapy is one of the platform therapies (interferon beta-1a, interferon beta-1b, glatiramer acetate) or an oral option (dimethyl fumarate, fingolimod). Your neurologist will guide the choice based on your disease activity, relapse frequency, and scheme coverage.

Step 3 — Register for CDL benefits with your scheme

Contact your scheme and register MS as a CDL condition. This unlocks dedicated chronic benefits for your DMT, neurologist consultations, and diagnostic investigations. Your neurologist or GP completes the CDL registration form.

Once registered, your scheme must fund your CDL-designated DMT. The platform therapies (interferon beta, glatiramer acetate) are typically funded as first-line CDL options.

Step 4 — Have an urgent conversation about your scheme's DMT coverage

This is the most important financial step for an MS patient — more important than gap cover, more important than plan selection within your current scheme.

Ask your scheme — in writing if possible: - Which DMTs do you fund as CDL first-line? - Is ocrelizumab available under exceptional needs, and what are the criteria? - Which DMTs require exceptional needs authorisation, and what is the approval process? - Is there a dedicated MS case management programme?

If your neurologist believes you have highly active MS or if you have PPMS, ocrelizumab access may be clinically necessary. Whether your scheme will fund it determines whether you can access the most effective available therapy.

Step 5 — Get your MRI baseline established

Your diagnostic MRI is your baseline. Future MRIs — typically annually for monitoring, or after a relapse — are compared to this baseline to detect new lesions. Make sure your neurologist has documented your baseline scan and that it is filed with your medical records.

MRI is expensive (brain + spine can run R3,000–R6,000 per scan at a private facility). Confirm your scheme's pre-authorisation requirements for annual monitoring MRI before booking.

Your Most Important Questions, Answered

Will I end up in a wheelchair? The trajectory varies enormously between individuals. Effective early treatment significantly reduces long-term disability risk. Many people with RRMS live decades with minimal disability. PPMS has a more progressive course, which is why ocrelizumab (the only PPMS-approved DMT) matters so much.

What happens during a relapse? A relapse (also called an attack or exacerbation) is a new neurological symptom or worsening of an old one, lasting at least 24 hours, not explained by fever or infection. Common relapse symptoms: limb weakness, vision changes (optic neuritis), tingling/numbness, balance problems, bladder symptoms. Many relapses are managed with a short course of IV methylprednisolone (a high-dose steroid that shortens the relapse). Not all relapses require treatment — speak to your neurologist.

Does my diet or lifestyle affect MS? Vitamin D deficiency is associated with higher MS risk and more severe disease. Supplementation is widely recommended (3,000–5,000 IU/day). Smoking is associated with faster progression — cessation matters. Exercise is beneficial and does not worsen MS.

What does this cost on medical aid? Platform therapies (interferon beta, glatiramer acetate) cost approximately R50,000/year — CDL-funded. High-efficacy therapies (ocrelizumab) cost R180,000–R250,000/year and require exceptional needs authorisation. The scheme you are on determines your access to high-efficacy therapy.

The Next Three Months

Your Scheme Coverage for MS

All CDL-registered schemes must fund MS management. The critical variable is high-efficacy DMT coverage. For patients on platform therapies with stable low-activity RRMS, most schemes provide adequate coverage.

For patients with highly active disease or PPMS who require ocrelizumab: scheme selection is the single most important healthcare decision you will make. AURA's role is to help you find the scheme that will fund the therapy your neurologist recommends.

Ready to check which scheme best covers your MS? Run your AURA check